emtricitabine, FTC (drug) — Competitive Intelligence Brief

emtricitabine, FTC (drug) (emtricitabine, FTC (drug)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside reverse transcriptase inhibitor (NRTI). Area: Infectious Disease / Virology.

phase 3 Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

emtricitabine, FTC (drug) (emtricitabine, FTC (drug)) — French National Agency for Research on AIDS and Viral Hepatitis. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and replicating.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
emtricitabine, FTC (drug) TARGET	emtricitabine, FTC (drug)	French National Agency for Research on AIDS and Viral Hepatitis	phase 3	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase
Emtricitabine / Tenofovir	Emtricitabine / Tenofovir	The Miriam Hospital	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV reverse transcriptase
Tenofovir/Emtricitabine and efavirenz	Tenofovir/Emtricitabine and efavirenz	GlaxoSmithKline	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase
Doravirine + tenofovir DF + lamivudine	Doravirine + tenofovir DF + lamivudine	Instituto Mexicano del Seguro Social	marketed	Antiretroviral combination (NNRTI + NRTIs)	HIV reverse transcriptase
Abacavir/lamivudine/zidovudine	Abacavir/lamivudine/zidovudine	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
Atazanavir/ Stavidine / Lamivudine	Atazanavir/ Stavidine / Lamivudine	Bristol-Myers Squibb	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
AZT+3TC+IDV+RTV	AZT+3TC+IDV+RTV	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + PI)	HIV reverse transcriptase; HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside reverse transcriptase inhibitor (NRTI) class)

1. French National Agency for Research on AIDS and Viral Hepatitis · 3 drugs in this class
2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
3. ViiV Healthcare · 2 drugs in this class
4. Nanfang Hospital, Southern Medical University · 2 drugs in this class
5. Asan Medical Center · 1 drug in this class
6. Dong-A ST Co., Ltd. · 1 drug in this class
7. Bristol-Myers Squibb · 1 drug in this class
8. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
9. Fu-Sheng Wang · 1 drug in this class
10. Avexa · 1 drug in this class